免疫检查点抑制剂治疗晚期胃癌的研究进展

Research Progress of Immune Checkpoint Inhibitors in the Treatment of Advanced Gastric Cancer

胃癌(gastric cancer, GC)是世界范围内癌症相关死亡原因第三位,其发病率及死亡率均位居全球恶性肿瘤的前五位。多数胃癌患者确诊时往往已进展至中晚期,缺乏有效的治疗手段,预后极差。尽管化疗和靶向治疗在内的内科治疗是目前晚期胃癌(advanced gastric cancer, AGC)的主要治疗手段,但因为胃癌的异质性,化疗和靶向治疗的疗效似乎已经达到平台期。近年来,免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)治疗在部分恶性肿瘤的治疗中取得重大进展,在AGC中,ICIs的疗效也被多项大规模研究进一步证实。本综述探讨了不同ICIs在晚期胃癌中的临床研究进展及近期研究数据。

Gastric cancer is the third leading cause of cancer-related deaths worldwide, and its incidence and mortality rates are among the top five malignant tumors in the world. Most patients with gastric cancer have already progressed to the middle and late stages when diagnosed, and lack of effective treatments, resulting in a very poor prognosis. Although medical treatment, including chemother-apy and targeted therapy, is currently the main treatment for advanced gastric cancer, the efficacy of chemotherapy and targeted therapy seems to have reached a plateau because of the heterogene-ity of gastric cancer. In recent years, immune checkpoint inhibitors (ICIs) therapy has made signifi-cant progress in the treatment of some malignant tumors, and the efficacy of ICIs has been further confirmed by several large-scale studies in AGC. This review discusses the progress of clinical stud-ies and recent research data of different ICIs in advanced gastric cancer.